about
Targeting Selectins and Their Ligands in CancerGlycosylation-Based Serum Biomarkers for Cancer Diagnostics and PrognosticsTargeting the Pim kinases in multiple myelomaDrugging the unfolded protein response in acute leukemiasA high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage responseThe sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaChronic myelogenous leukaemia--new therapeutic principles.STI571: a paradigm of new agents for cancer therapeutics.Recent advancements in the treatment of chronic myelogenous leukemia.TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Multifaceted approach to the treatment of bcr-abl-positive leukemias.Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.STI571 as a targeted therapy for CML.Targeting AML through DR4 with a novel variant of rhTRAILIbrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular ModelsHow to monitor patients with chronic myelogenous leukemia.Cdc7 kinase - a new target for drug development.5-Azacytidine for the treatment of myelodysplastic syndromes.Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma.Perifosine--a new option in treatment of acute myeloid leukemia?The role of inflammation in leukaemia.AKT as a therapeutic target in multiple myeloma.The cancer glycome: carbohydrates as mediators of metastasis.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Neurotrophins and B-cell malignancies.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members.Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.Home administration of bortezomib: making a difference to myeloma patients' lives.Clofarabine in the treatment of poor risk acute myeloid leukaemia.Outcome in elderly acute myeloid leukaemia.Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
P50
Q26752384-5418DF07-26D2-4CF7-97CF-391A5BC9DD2AQ26778227-F80BECBC-E3A8-4CFC-B8CE-C859DC5D3937Q26799499-577106E6-1EFF-454E-9073-F1AC08794000Q26801114-A0BA9F07-E026-40A2-94D2-40DC494AD79CQ28539430-A31A62FF-4EFF-41D0-94C5-7E886924F94EQ34170367-7CCA3852-D1F7-4B60-9D89-76943BD37B02Q34308917-955B2C56-222E-4939-BDF4-E4D56A77545EQ34482385-B9B98BC8-63F9-4A46-9FEE-1E422AEA8F08Q34511570-7487CBA8-CD49-4761-A441-74B0ECFE03C0Q34564468-116E6650-EDAB-449F-BBE5-7912E4F1A3F4Q34605832-00E9D1DA-6603-442C-A31B-2864DC9D5E3DQ34718219-29BC9B5F-E3A3-4337-B6C9-9AC5C54A7036Q35193288-9FA37652-387F-4E07-BB6B-93126414BFA5Q35377418-A1DCE44F-7023-4EE5-AA8F-2D47C9C76561Q36490049-768247B1-F1EF-4947-919E-63689D5B9956Q37129891-F2AE71D4-9147-4D9C-842A-940EBECFE525Q37226506-F98475E5-1FE4-4464-951B-2C1E6C2A75CEQ37602112-E0A079DC-48BC-42DC-AAA0-A40537E3428DQ37611280-867F3359-6604-477A-9DC1-F84FFD081AC5Q38102062-E26C0A2A-726C-4D66-BA95-8F8CB9EAEF6EQ38111315-2E5F6223-7221-4C3C-A2D4-ABD865F35009Q38127844-7EE591A9-1A64-4C2C-A05F-04E4AF748A21Q38211084-459A7BE1-C4A2-4726-8F74-E0C486F2B5BBQ38218256-8889CE5B-D128-4FD6-A9F1-25ACAB47FE67Q38337953-BF68B7EC-BF6E-4C75-8D4F-E480E8F1323DQ38550480-5568FD12-5066-47C7-8E7E-87C92770B6D3Q38591883-2938C57E-9721-4718-82DE-31068B78A74CQ38820002-6C723B64-8931-49AE-904B-F091A384CA06Q38821948-87FDAB0D-A7DB-4651-8546-DEB69090D824Q39189380-F34092A1-93A7-48B1-877C-A1528F500476Q39732225-84FAD42A-5743-4C40-84AB-197074B6751FQ40664033-5D7EAAC4-9437-42E5-8DF3-F77E8540FEAFQ40716128-23EBFDE4-6478-4390-B747-FE936BEA14ADQ40838410-CA004412-DD1B-4B7F-B02A-5B2016439A48Q42808038-735E1CC3-4D04-4996-8956-1553EC68FC12Q43264240-351EA0F0-E0B6-4919-9886-772BD55825B8Q43273726-886944D2-CD02-495B-93D9-88725EFD84C2Q43602584-17016B48-8630-4BAB-95A5-B174AFD5998EQ44045908-11A565BF-A2F3-499A-906C-55B9C3374E1AQ44101981-25CF164A-85EB-4753-914D-1343943D6A58
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Michael O'Dwyer
@ast
Michael O'Dwyer
@en
Michael O'Dwyer
@en-gb
Michael O'Dwyer
@es
Michael O'Dwyer
@nl
Michael O'Dwyer
@sl
type
label
Michael O'Dwyer
@ast
Michael O'Dwyer
@en
Michael O'Dwyer
@en-gb
Michael O'Dwyer
@es
Michael O'Dwyer
@nl
Michael O'Dwyer
@sl
prefLabel
Michael O'Dwyer
@ast
Michael O'Dwyer
@en
Michael O'Dwyer
@en-gb
Michael O'Dwyer
@es
Michael O'Dwyer
@nl
Michael O'Dwyer
@sl
P106
P31
P496
0000-0002-6173-7140